Christophe Louvet

Summary

Country: France

Publications

  1. pmc Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
    Volker Heinemann
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 8:82. 2008
  2. ncbi request reprint [Gemcitabine-based combinations in inoperable pancreatic cancers]
    Christophe Louvet
    Service d Oncologie, Medecine Interne, Hopital Saint Antoine, 184, rue du Faubourg Saint Antoine, 75012 Paris
    Bull Cancer 89:S96-101. 2002
  3. ncbi request reprint Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)
    C Louvet
    Service l Oncologie, Hĵpital Saint Antoine, Paris, France
    Ann Oncol 12:675-9. 2001
  4. ncbi request reprint Pemetrexed in advanced colorectal cancer
    Christophe Louvet
    Hopital St Antoine, Service de Medecine Int Onc, Paris, France
    Oncology (Williston Park) 18:56-62. 2004
  5. ncbi request reprint Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study
    C Louvet
    Service d Oncologie Médecine Interne, Hopital Saint Antoine, Service d Oncologie, Hopital Tenon, and GERCOR, Paris, France
    J Clin Oncol 20:1512-8. 2002
  6. ncbi request reprint Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice
    C Louvet
    INSERM Unit 482, Hopital St Antoine, Paris, France
    Anticancer Drugs 11:579-82. 2000
  7. ncbi request reprint [Indications and methods for adjuvant chemotherapy of colonic cancer]
    C Louvet
    Service d Oncologie, Hopital Saint Antoine, 184, rue du Faubourg Saint Antoine, 75012 Paris, France
    Pathol Biol (Paris) 52:119-22. 2004
  8. ncbi request reprint Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients
    C Louvet
    Service d Oncologie Médecine Interne, Hopital Saint Antoine, Paris, France
    J Clin Oncol 20:4543-8. 2002
  9. ncbi request reprint Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen)
    Christophe Louvet
    Service de médecine interne oncologie, Hopital St Antoine, 184 rue du fbg St Antonie, 75012, Paris, France
    Cancer Invest 21:14-20. 2003
  10. ncbi request reprint Colorectal cancer: integrating oxaliplatin
    Christophe Louvet
    Service d Oncologie, Hopital St Antoine, 184 rue du Faubourg St Antoine, 75012 Paris, France
    Curr Treat Options Oncol 4:405-11. 2003

Detail Information

Publications75

  1. pmc Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
    Volker Heinemann
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 8:82. 2008
    ..Single-agent gemcitabine (GEM) is a standard treatment for advanced and metastatic pancreatic cancer. This study examines the question whether GEM-based combination chemotherapy can further improve treatment efficacy...
  2. ncbi request reprint [Gemcitabine-based combinations in inoperable pancreatic cancers]
    Christophe Louvet
    Service d Oncologie, Medecine Interne, Hopital Saint Antoine, 184, rue du Faubourg Saint Antoine, 75012 Paris
    Bull Cancer 89:S96-101. 2002
    ..We summarize the results of studies combining gemcitabine with 5FU, docetaxel, platinum-compounds, irinotecan and epirubicin. Some combinations seem to achieve an interesting efficacy, and are now compared to gemcitabine alone...
  3. ncbi request reprint Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)
    C Louvet
    Service l Oncologie, Hĵpital Saint Antoine, Paris, France
    Ann Oncol 12:675-9. 2001
    ..This study was designed to test the efficacy of the leucovorin 5-FU and gemcitabine combination...
  4. ncbi request reprint Pemetrexed in advanced colorectal cancer
    Christophe Louvet
    Hopital St Antoine, Service de Medecine Int Onc, Paris, France
    Oncology (Williston Park) 18:56-62. 2004
    ..All of these trials include vitamin supplementation. A phase III trial comparing the every-3-week pemetrexed/oxaliplatin regimen with FOLFOX4 as first-line treatment will be initiated if the outcome of the phase II trial is encouraging...
  5. ncbi request reprint Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study
    C Louvet
    Service d Oncologie Médecine Interne, Hopital Saint Antoine, Service d Oncologie, Hopital Tenon, and GERCOR, Paris, France
    J Clin Oncol 20:1512-8. 2002
    ..Based on preclinical in vitro synergy data, this study evaluated the activity and toxicity of a gemcitabine/oxaliplatin combination in patients with metastatic and locally advanced pancreatic adenocarcinoma...
  6. ncbi request reprint Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice
    C Louvet
    INSERM Unit 482, Hopital St Antoine, Paris, France
    Anticancer Drugs 11:579-82. 2000
    ..05) or UFT/FA (p<0.05). These results demonstrate the synergistic effect of the combination of oxaliplatin, UFT and FA in this HT29 cell xenograft model, and warrant further investigations in patients with metastatic colorectal cancer...
  7. ncbi request reprint [Indications and methods for adjuvant chemotherapy of colonic cancer]
    C Louvet
    Service d Oncologie, Hopital Saint Antoine, 184, rue du Faubourg Saint Antoine, 75012 Paris, France
    Pathol Biol (Paris) 52:119-22. 2004
    ..It is an option for stage II patients. Elderly patients could be treated according to the same modalities as younger patients, based on physiological age and relative contra-indications from associated diseases...
  8. ncbi request reprint Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients
    C Louvet
    Service d Oncologie Médecine Interne, Hopital Saint Antoine, Paris, France
    J Clin Oncol 20:4543-8. 2002
    ..To evaluate the efficacy and safety of an oxaliplatin, fluorouracil (5-FU), and folinic acid (FA) combination in patients with metastatic or advanced gastric cancer (M/AGC)...
  9. ncbi request reprint Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen)
    Christophe Louvet
    Service de médecine interne oncologie, Hopital St Antoine, 184 rue du fbg St Antonie, 75012, Paris, France
    Cancer Invest 21:14-20. 2003
    ..Response rate and survival in patients with gastric linitis or diffuse forms were in the same range as in patients with intestinal forms of gastric adenocarcinoma...
  10. ncbi request reprint Colorectal cancer: integrating oxaliplatin
    Christophe Louvet
    Service d Oncologie, Hopital St Antoine, 184 rue du Faubourg St Antoine, 75012 Paris, France
    Curr Treat Options Oncol 4:405-11. 2003
    ..The tolerance of the oxaliplatin/5-FU combination allows for design regimens integrating new drugs, such as biologic modifiers...
  11. ncbi request reprint Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial
    C Louvet
    Service d Oncologie, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    J Clin Oncol 23:3509-16. 2005
    ..Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phase III study comparing GemOx with Gem alone in advanced pancreatic cancer...
  12. ncbi request reprint Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
    Anne Marie Coudray
    INSERM U482, Signal Transduction and Cellular Functions in Diabetes and Digestive Cancers, Paris, France
    Int J Oncol 27:553-61. 2005
    ..These encouraging results warrant further preclinical investigations and clinical trials on the use of BGC9331 combined with SN-38/CPT-11 in treatment of patients with advanced colorectal or gastric cancers...
  13. doi request reprint Platinum-sensitivity in metastatic colorectal cancer: towards a definition
    Benoist Chibaudel
    Department of Medical Oncology, Hopital Saint Antoine, APHP, Paris, France Université Pierre et Marie Curie, Universite Paris 6, Paris, France GERCOR, Groupe Coopérateur Multidisciplinaire en Oncologie, Paris, France Electronic address
    Eur J Cancer 49:3813-20. 2013
    ..Influence of the first-line oxaliplatin-based treatment efficacy and the duration of OFI on tumour sensitivity to oxaliplatin reintroduction were investigated...
  14. ncbi request reprint Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer
    Aimery de Gramont
    Hopital Saint Antoine, Paris Cedex 12, France
    J Clin Oncol 25:3224-9. 2007
    ....
  15. doi request reprint Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study
    Benoist Chibaudel
    Hopital Saint Antoine, Paris Cedex 12, France
    J Clin Oncol 27:5727-33. 2009
    ....
  16. ncbi request reprint Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1
    Thierry Andre
    Public Hôpitaux de Paris and CancerEst, Hopital Tenon, Paris, France
    J Clin Oncol 25:3732-8. 2007
    ....
  17. ncbi request reprint Adjuvant therapy for stage II and III colorectal cancer
    Aimery de Gramont
    Groupe Coopérateur Multidisciplinaire en Oncologie, Hopital Saint Antoine, Service de médecine interne oncologie, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Semin Oncol 34:S37-40. 2007
    ..Studies are ongoing to identify optimal adjuvant regimens in stage II or III disease and to identify the potential benefits of adding bevacizumab or cetuximab to adjuvant therapy...
  18. ncbi request reprint Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer
    May Mabro
    Department of Medical Oncology, Hopital Saint Antoine, Paris, France
    Am J Clin Oncol 26:254-8. 2003
    ..FOLFIRI-2 achieved a good rate of response and stabilization in heavily pretreated patients despite significant toxicity...
  19. pmc Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study
    Benoist Chibaudel
    Department of Medical Oncology, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Oncologist 16:1228-38. 2011
    ..The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer...
  20. doi request reprint Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1)
    Isabelle Baumgaertner
    Department of Hepatogastroenterology, Hopital Pitie Salpetriere, Paris, France
    Clin Colorectal Cancer 9:E5-10. 2010
    ..These analyses compare the safety and efficacy of 2 forms (levogyre [L] and dextro-levogyre [DL]) of leucovorin (LV) when used with 5-fluorouracil (5-FU) for the adjuvant treatment of patients with stage II and III colon cancer...
  21. doi request reprint Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en O
    Laurence Moureau-Zabotto
    Hopital Tenon, Service de Radiotherapie, 4 rue de la Chine, 75020 Paris, France
    J Clin Oncol 26:1080-5. 2008
    ....
  22. ncbi request reprint Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment
    Suzanne Nguyen
    Service d Oncologie, Centre Hospitalier, 40 avenue Léon Blum, 60021 Beauvais Cedex, France
    Bull Cancer 93:E1-6. 2006
    ..We report here the results of these two phase II studies...
  23. ncbi request reprint FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
    Christophe Tournigand
    Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
    J Clin Oncol 22:229-37. 2004
    ..This phase III study investigated two sequences: folinic acid, FU, and irinotecan (FOLFIRI) followed by folinic acid, FU, and oxaliplatin (FOLFOX6; arm A), and FOLFOX6 followed by FOLFIRI (arm B)...
  24. ncbi request reprint Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial
    Thierry Andre
    Hopital Tenon, Groupe d Etude et de Recherche Clinique en Oncologie Radioitherapie, Paris
    J Clin Oncol 21:2896-903. 2003
    ....
  25. ncbi request reprint Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells
    Eric Raymond
    INSERM U482, Hopital Saint Antoine, Paris, France
    Int J Oncol 21:361-7. 2002
    ..These results argue in favor of clinical trials of chemotherapy combining MTA with oxaliplatin or irinotecan (CPT-11), for the treatment of patients with colon cancer...
  26. ncbi request reprint Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission
    Christophe Tournigand
    Service d Oncologie Medicale, Hopital Saint Antoine, Paris, France
    Gynecol Oncol 91:341-5. 2003
    ....
  27. ncbi request reprint OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study
    Christophe Tournigand
    Hopital Saint Antoine, Paris, France
    J Clin Oncol 24:394-400. 2006
    ..This study evaluates a new strategy of intermittent oxaliplatin treatment that is based on FOLFOX7, a simplified leucovorin and fluorouracil regimen with high-dose oxaliplatin...
  28. doi request reprint From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Semin Oncol 38:521-32. 2011
    ..Clarity regarding the clinical signal needed before launching a phase III study and optimized designs adapted to multiple agents are urgently needed for new trials...
  29. ncbi request reprint Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients
    Frédérique Maindrault-Goebel
    Saint Antoine Hospital, Oncology Department, 184, rue du Saint Faubourg, Saint Antoine, 75571 Paris, Cedex 12, France
    Eur J Cancer 41:2262-7. 2005
    ..For the non-life-threatening reactions, prolonging infusion duration, "Stop and Go" regimen seem to be effective means of preventing recurrence...
  30. doi request reprint S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma
    Jean Baptiste Bachet
    Medical University Pierre et Marie Curie, UFR Paris VI, 91 105 boulevard de l Hôpital, Paris, France
    Eur J Cancer 49:2643-53. 2013
    ..S100A2 has been recently suggested as a negative prognostic biomarker in PAC. We aimed to investigate its prognostic and/or predictive value in a large independent multicentric cohort of patients with resected PAC...
  31. ncbi request reprint High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)
    F Maindrault-Goebel
    , , 184 rue du Faubourg Saint-Antoine, 75571 cedex 12, Paris, France
    Eur J Cancer 37:1000-5. 2001
    ..FOLFOX7 was highly active, with good tolerability, in pretreated patients resistant to LV-5-FU [corrected]...
  32. doi request reprint Stage II and stage III colon cancer: treatment advances and future directions
    Benoit Rousseau
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, France
    Cancer J 16:202-9. 2010
    ..Adjuvant therapy in elderly patients is another matter of debate due to the lack of survival advantage in the recent trials...
  33. ncbi request reprint Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer
    F Maindrault-Goebel
    Service de médecine interne oncologie, Hopital Saint Antoine, Paris, France
    Ann Oncol 15:1210-4. 2004
    ..This retrospective study investigated FOLFOX reintroduction after a break in treatment or following disease progression on another regimen...
  34. ncbi request reprint Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study
    T Andre
    Hopital Tenon, Department of Medical Oncology, Paris, France
    Ann Oncol 18:77-81. 2007
    ..Celecoxib is an anti-cyclooxygenase-2 drug with anti-neoplastic properties. In the present study, celecoxib was evaluated in combination with FOLFOX7 regimen and as a single agent in maintenance therapy...
  35. ncbi request reprint Targeted agents for adjuvant therapy of colon cancer
    Aimery de Gramont
    GERCOR Groupe Coopérateur Multidisciplinaire en Oncologie and Hôpital Saint Antoine, Paris, France
    Semin Oncol 33:S42-5. 2006
    ..Cetuximab is being evaluated in combination with FOLFOX4 and FOLFOX6 in the North Central Cancer Treatment Group (NCCTG) N0147 trial and the Pan European Trials in Adjuvant Colon Cancer (PETTAC) 8 trial...
  36. ncbi request reprint Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2)
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris
    Gastroenterol Clin Biol 28:645-50. 2004
    ..The aims of this phase II multicentric study were to evaluate the response rate, clinical benefit and tolerance of a new scheme of combined leucovorin, 5-FU and gemcitabine (FOLFUGEM 2)...
  37. ncbi request reprint Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer
    J Taieb
    Médecine Interne Oncologie, Hopital St Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Eur J Cancer 38:661-6. 2002
    ..There were no treatment-related deaths. These results suggest that the HLFP regimen is an active and well-tolerated chemotherapy for metastatic oesophageal carcinoma...
  38. doi request reprint Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin
    A Zaanan
    INSERM, UMR_S 938, Saint Antoine Research Centre, 184 rue du Faubourg Saint Antoine, Paris Cedex 12, France
    Ann Oncol 21:772-80. 2010
    ....
  39. doi request reprint Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy
    Aziz Zaanan
    Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, AP HP, Paris, France
    Clin Cancer Res 17:7470-8. 2011
    ..The aim of this study was to evaluate the prognostic value of MMR status for DFS in patients with stage III colon cancer receiving adjuvant FOLFOX chemotherapy...
  40. pmc Current status of adjuvant therapy for colon cancer
    Thierry Andre
    Hopital Tenon, Paris, France
    Gastrointest Cancer Res 1:90-7. 2007
    ..Duration of therapy and prevention of oxaliplatin neurotoxicity are other critical areas for future research...
  41. ncbi request reprint First-line therapy for advanced colorectal cancer
    Aimery de Gramont
    Service de médecine interne oncologie, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
    Curr Oncol Rep 7:167-72. 2005
    ..Furthermore, we fear that limited financial resources will also influence the management of this disease...
  42. ncbi request reprint [Colon cancer: what is new in 2004?]
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris, France
    Bull Cancer 91:75-80. 2004
    ..Shrinkage of tumours after administration of preoperative chemotherapy and availability of ablative techniques (radiofrequency and cryotherapy) now allow to treat with curative intent metastases initially considered as non-resectable...
  43. pmc Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
    T Andre
    Department of Medical Oncology, Hopital Tenon, université Paris 06, Paris 75020, France
    Br J Cancer 99:862-7. 2008
    ..4%), anaemia (10.4%), neutropenia (11.9%) and pain (1 1.9%). In this study, GEMOX demonstrated activity in non-gallbladder carcinoma, but poor activity in gallbladder carcinoma. GEMOX is well tolerated in advanced BTCs...
  44. ncbi request reprint Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors
    Pierre Blanchard
    Service d Oncologie Medicale, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75012, Paris, France
    Gynecol Oncol 104:41-5. 2007
    ..Relapses of epithelial ovarian carcinoma (EOC) have a poor prognosis. Isolated lymph node relapses (ILNR) are considered of relatively good prognosis with intensive therapy...
  45. ncbi request reprint The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy
    Samir Attoub
    INSERM U482, Signal Transduction and Cellular Functions in Diabetes and Digestive Cancers, Hopital Saint Antoine, 75571 Paris Cedex 12, France
    Cancer Res 62:4879-83. 2002
    ....
  46. doi request reprint First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study
    P Afchain
    Service d Oncologie, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Bull Cancer 96:E18-22. 2009
    ..GemOx was defined as a D1-D2 schedule, based on preclinical data. In order to improve convenience for patients, we evaluated a simplified D1-D1 GemOx regimen (S-GemOx) in MPA...
  47. doi request reprint FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study
    B Chibaudel
    Department of Medical Oncology, Saint Antoine Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Ann Oncol 20:1383-6. 2009
    ..Patients with ALP more than three times the upper limit of normal (ULN) were excluded from our previous studies evaluating chemotherapy. An exploratory cohort of patients with ALP >3 ULN was included in the OPTIMOX1 study...
  48. ncbi request reprint Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma
    C Louvet
    Department of Medical Oncology, Hopital Saint Antoine, Pavillon Moïana, Paris, France
    Cancer 91:2033-8. 2001
    ..Measuring progression free survival (PFS) may be a means of isolating the real impact of first-line regimens...
  49. doi request reprint Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study
    F C Bidard
    Department of Medical Oncology, Hospital Saint Antoine, Paris, France
    Ann Oncol 20:1042-7. 2009
    ..Second-line irinotecan-based chemotherapy is commonly used in metastatic colorectal cancers after first-line oxaliplatin-based chemotherapy. No standard schedule of irinotecan has been established in this situation...
  50. ncbi request reprint [Long term survival in metastatic colorectal cancer treated with leucovorin and 5-fluoro-uracil chemotherapy]
    N Perez
    Service de médecine interne oncologie, Hopital Saint Antoine, Paris, France
    Rev Med Interne 25:124-8. 2004
    ..Median survival in advanced colorectal cancer patients treated with 5-fluoro-uracil (5FU) and leucovorin (LV) is between 12 and 18 months. The aim of this study was to evaluate long term survival in this disease...
  51. ncbi request reprint [Oxaliplatin in combination with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer]
    T Andre
    Hopital Tenon, 4, rue de la Chine, 75020 Paris, France
    Bull Cancer 88:S20-5. 2001
    ....
  52. ncbi request reprint A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients
    C Louvet
    Service d Oncologie, Hopital Saint Antoine, 184, rue du Faubourg Saint Antoine, 75012 Paris, France
    Bull Cancer 91:279-84. 2004
    ....
  53. ncbi request reprint Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies
    T Andre
    Service d Oncologie Medicale, H pital Tenon, Paris, France
    Semin Oncol 28:35-40. 2001
    ..001). Although patients in the LV5FU2 group received twice the dose of 5-FU compared with those in the FUFOL group, LV5FU2 was shown to be less toxic. Efficacy data will be available in 2001...
  54. ncbi request reprint Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma
    C Tournigand
    Service d Oncologie Medicale, Hopital Saint Antoine, Paris, France
    Gynecol Oncol 83:198-204. 2001
    ..We evaluated a multimodal treatment strategy integrating these therapeutic options...
  55. ncbi request reprint Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    A de Gramont
    Service de médecine interne oncologie, Hopital Saint Antoine, Paris, France
    J Clin Oncol 18:2938-47. 2000
    ..This phase III study investigated the effect of combining oxaliplatin with LV5FU2, with progression-free survival as the primary end point...
  56. ncbi request reprint Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study
    T Andre
    Department of Medical Oncology, University Hospital, Grenoble, France
    Int J Radiat Oncol Biol Phys 46:903-11. 2000
    ..The quality of palliation and percentage of secondary resections were also studied for unresectable disease...
  57. ncbi request reprint Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
    T Andre
    Hopital Tenon, Clinique du Mont Louis, Paris, France
    J Clin Oncol 17:3560-8. 1999
    ....
  58. ncbi request reprint [Adenocarcinoma of the pancreas. Therapeutic strategies]
    T Andre
    Service d Oncologie Medicale, Hopital Tenon, Paris
    Presse Med 27:539-45. 1998
    ..After complete resection 70 to 80% of patients develop a local recurrence. Biliary and gastro-intestinal bypasses as well as antalgic techniques are useful palliative procedures...
  59. ncbi request reprint [Adenocarcinoma of the pancreas. General characteristics]
    T Andre
    Service d Oncologie Medicale, Hopital Tenon, Paris
    Presse Med 27:533-6. 1998
    ..Few risk factors have been identified. Smoking increases the relative risk by 1.5, chronic pancreatitis by 26. Hereditary formes are rare...
  60. ncbi request reprint Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study
    T Andre
    Oncology Department, Tenon Hospital, Paris, France
    Ann Oncol 15:1339-43. 2004
    ..Since gemcitabine-oxaliplatin (GEMOX) has been used in pancreatic adenocarcinoma, we studied its activity and tolerability in advanced biliary tract adenocarcinoma (ABTA)...
  61. doi request reprint Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis
    Coralie Dorard
    Institut National de la Sante et de la Recherche Medicale INSERM, Centre de Recherche Saint Antoine, Equipe Instabilité des Microsatellites et Cancers, Paris, France
    Nat Med 17:1283-9. 2011
    ..The survival and response to chemotherapy of subjects with MSI CRCs was associated with the tumor expression level of HSP110ΔE9. HSP110 may thus constitute a major determinant for both prognosis and treatment response in CRC...
  62. pmc Antiproliferative effects of the arotinoid Ro 40-8757 in human gastrointestinal and pancreatic cancer cell lines: combinations with 5-fluorouracil and interferon-alpha
    C Louvet
    , , Paris, France
    Br J Cancer 74:394-9. 1996
    ..Our data support the interest in Ro 40-8757 as a potent anti-cancer drug, especially in combination therapy with 5FU and interferon, in gastrointestinal and pancreatic cancers, where new active therapeutic modalities are urgently needed...
  63. ncbi request reprint [Meningeal carcinomatosis in gastric cancer]
    L Vedrine
    , , Paris, France
    Gastroenterol Clin Biol 25:422-4. 2001
    ..This diagnosis should be evoked in the presence of unexplained neurologic symptoms and confirmed by CSF examination in order to propose a treatment and to delay serious neurologic disability and prolong survival...
  64. ncbi request reprint [What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?]
    Jean Louis Legoux
    Services d Hépato gastroentérologie, Hopital Haut Leveque, CHU de Bordeaux, Pessac
    Gastroenterol Clin Biol 30:1191-5. 2006
  65. ncbi request reprint Cetuximab efficacy in patients treated routinely in university hospitals
    Jean Baptiste Bachet
    Hopital Ambroise Pare, APHP, Boulogne, Universite de Versailles Saint Quentin en Yvelines, UFR Paris Ile de France Ouest
    Gastroenterol Clin Biol 31:941-9. 2007
    ..The aim of this study was to evaluate the efficacy and tolerance of cetuximab (Cx) in patients with irinotecan-refractory metastatic colorectal cancer (IRMCRC) treated routinely at five university hospitals...
  66. ncbi request reprint Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies
    Florence Huguet
    Department of Radiation Oncology, Tenon Hospital, Assistance Publique Hopitaux de Paris, France
    J Clin Oncol 25:326-31. 2007
    ..The decision to administer CRT or continue CT in nonprogressive patients was the investigator's choice...
  67. ncbi request reprint Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study
    Julien Taieb
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    J Clin Oncol 23:502-9. 2005
    ..To evaluate the efficacy and tolerability of the metastatic irinotecan plus oxaliplatin (MIROX) strategy (adjuvant FOLFOX-7 followed by FOLFIRI), in patients with resectable metastatic colorectal cancer...
  68. ncbi request reprint Assessment of management practices for colonic cancer in the Paris metropolitan area in 2002
    Lina Silvéra
    Direction Régionale du Service Médical de l Assurance Maladie d Ile de France, Paris
    Gastroenterol Clin Biol 30:852-8. 2006
    ..To assess the management of patients aged 18 years or older with colonic adenocarcinoma (including the rectosigmoid junction), compared with French guidelines (ANAES and SOR)...
  69. ncbi request reprint Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study)
    Mohamed Hebbar
    Unité d Oncologie Médicale, Hôpital Huriez CHRU, Lille, France
    Cancer Invest 24:154-9. 2006
    ..1 percent). Median progression-free and overall survivals were 8.8 and 18.7 months, respectively. Only 2 patients (5.1 percent) had Grade 3 oxaliplatin-related sensory-neuropathy. This schedule had so promising efficacy and safety...
  70. ncbi request reprint [Anti-angiogenic treatment and colorectal cancer]
    Thierry Andre
    Service d Oncologie Medicale, Hopital Tenon, 4, rue de la Chine, 75970 Paris Cedex 20
    Bull Cancer 94:S211-9. 2007
    ..Several questions regarding the optimal use of bevacizumab still remain to be answered in the treatment of metastastic colorectal cancer. Vatalanib has not shown benefit in this pathology...
  71. ncbi request reprint FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study
    Arie Figer
    Beth Sourasky Medical Center Tel Aviv, Israel
    Cancer 110:2666-71. 2007
    ..An exploratory cohort of patients aged 76 to 80 years was included in the study...
  72. doi request reprint KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
    Astrid Lievre
    L Institut National de la Santé et de la Recherche Médicale U775, Universite Paris Descartes, 45 Rue des Saints Peres, 75006 Paris, France
    J Clin Oncol 26:374-9. 2008
    ..The aim of this study was to validate, in an independent larger series of 89 patients, the prognostic value of KRAS mutations on response to cetuximab and survival...
  73. ncbi request reprint [Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)]
    Thierry Conroy
    Centre Alexis Vautrin, Nancy
    Bull Cancer 91:759-68. 2004
    ..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
  74. ncbi request reprint [Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus]
    Pierre Nahon
    Gastroenterol Clin Biol 27:555-6. 2003
  75. ncbi request reprint [Radiofrequency ablation of an unresectable abdominal tumor]
    Alain Sezeur
    Service de Chirurgie Digestive et Endocrinienne, Hopital des Diaconesses, Paris
    Gastroenterol Clin Biol 27:233-5. 2003
    ..No adjuvant treatment was proposed because of intolerance to chemotherapy. Clinical assessment and thoracic and abdominal CT scan confirmed the absence of recurrence 26 months after radiofrequency ablation. Serum markers remained normal...